Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gp100 Vaccine with Adjuvants in High-Risk Melanoma
NCT00273910Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2006
- Primary completion
- May 2010
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gp100:209-217 in melanoma, sponsored by National Cancer Institute. Started Jan 2006; status: completed.
02
Drugs
gp100:209-217
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00273910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00273910.